about
Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta-analysis of Randomized Controlled TrialsValidation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness methodUnderstanding heart failure; explaining telehealth - a hermeneutic systematic review.Effects of renal sympathetic denervation on post-myocardial infarction cardiac remodeling in rats.Is treatment with trimetazidine beneficial in patients with chronic heart failure?Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trialsReviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.Adrenergic Repression of the Epigenetic Reader MeCP2 Facilitates Cardiac Adaptation in Chronic Heart Failure.Deleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction.Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjectsClinical effects of Xinmailong therapy in patients with chronic heart failure.Aggravated myocardial infarction-induced cardiac remodeling and heart failure in histamine-deficient mice.Hydrogen sulfide attenuates the recruitment of CD11b⁺Gr-1⁺ myeloid cells and regulates Bax/Bcl-2 signaling in myocardial ischemia injury.Can medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model.Left ventricular restoration devices.The pathophysiology of pulmonary hypertension in left heart disease.Drug-Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling.Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy.Hydrogen Sulfide Reduces Recruitment of CD11b+Gr-1+ Cells in Mice With Myocardial Infarction.High prevalence of iron deficiency in patients with acute decompensated heart failure.[Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.Cardiac Actions of a Small Molecule Inhibitor Targeting GATA4-NKX2-5 Interaction.
P2860
Q26785479-0B173216-D6AC-4CF3-947D-4C7E72DB7EF9Q30525580-01061EBA-6ADF-4CDB-BBDC-1CA0ADB2984AQ30855803-8C6C97FD-28CC-4ECB-A1DD-1013708C6103Q31103227-C317A1BE-29E4-45AE-88C1-1C46325E134EQ33567682-E70856B9-3BCA-45F8-870E-DAE1B6062C80Q33791471-C1506EF0-6574-465F-8C09-10B7A22C9EF6Q35900749-55AC1940-1C9A-452C-ABB1-6AA5A5EA1D98Q36057402-283C4126-BB81-44D6-8433-5C558E1EC7F3Q36522680-0C908ABD-96B7-4890-B8EE-B94CCB54D499Q36645693-93EB991C-F4A3-4CAA-999F-C006C3DC395BQ36746865-12B5310E-E808-4E25-8CD4-6CFF6CDF5EB7Q37685771-2A9C6178-3019-4C00-ACC0-F1E099777F1FQ37720537-7198AF95-0C63-41ED-B1BF-54A15BC145B3Q38115658-185A652D-066E-48A6-AC5F-0B8D7C174513Q38191509-675FB92D-C6B1-439F-A701-393188B1F634Q38616615-43585ABF-E2FE-439D-B757-70CAE07FCD56Q38676235-99961A49-F325-43DB-A555-A0CBDDD4EBADQ39635805-1757C40A-D6BB-4CB2-8DFC-CCEE7092FF31Q47160162-F2CCA4F1-C704-4284-BAD3-7F85BC8CED1FQ47744173-DD1AB184-F95C-4E29-8FC9-3136EE5AA75CQ50457479-8E32FC9B-770C-4D16-86F1-9D26C38E5C6EQ55286667-4CAC2B99-0ABA-40FC-B129-79A6E6F30A34Q55334799-A70F3C90-B441-4A0E-9A92-D4E0E0426114
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Medical therapy for chronic heart failure.
@en
Medical therapy for chronic heart failure.
@nl
type
label
Medical therapy for chronic heart failure.
@en
Medical therapy for chronic heart failure.
@nl
prefLabel
Medical therapy for chronic heart failure.
@en
Medical therapy for chronic heart failure.
@nl
P1433
P1476
Medical therapy for chronic heart failure.
@en
P2093
John R Teerlink
P304
P356
10.1016/S0140-6736(11)61038-6
P407
P50
P577
2011-08-01T00:00:00Z